These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 1407012

  • 1. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E, Lindén IB, Schultz E, Pohto P.
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.
    Törnwall M, Kaakkola S, Tuomainen P, Kask A, Männistö PT.
    Br J Pharmacol; 1994 May; 112(1):13-8. PubMed ID: 7518301
    [Abstract] [Full Text] [Related]

  • 3. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T, Prikhojan A, Yahr MD.
    J Neural Transm (Vienna); 1997 May; 104(1):77-87. PubMed ID: 9085195
    [Abstract] [Full Text] [Related]

  • 4. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.
    Kaakkola S, Wurtman RJ.
    J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137
    [Abstract] [Full Text] [Related]

  • 5. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A, Bellini G, Borroni E, Zürcher G, Bonuccelli U.
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [Abstract] [Full Text] [Related]

  • 6. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A, Loureiro AI, Vieira-Coelho MA, Hainzl D, Soares-da-Silva P.
    Eur J Pharmacol; 2001 May 18; 420(1):27-32. PubMed ID: 11412836
    [Abstract] [Full Text] [Related]

  • 7. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, Riederer P.
    J Neural Transm (Vienna); 2001 May 18; 108(2):189-204. PubMed ID: 11314772
    [Abstract] [Full Text] [Related]

  • 8. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat.
    Männistö PT, Tuomainen P, Tuominen RK.
    Br J Pharmacol; 1992 Mar 18; 105(3):569-74. PubMed ID: 1628144
    [Abstract] [Full Text] [Related]

  • 9. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase.
    Törnwall M, Tuomainen P, Männistö PT.
    Eur J Pharmacol; 1993 Aug 03; 239(1-3):39-45. PubMed ID: 8223912
    [Abstract] [Full Text] [Related]

  • 10. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
    Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T.
    Clin Neuropharmacol; 1993 Apr 03; 16(2):145-56. PubMed ID: 8477410
    [Abstract] [Full Text] [Related]

  • 11. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
    Pauwels T, Dethy S, Goldman S, Monclus M, Luxen A.
    Eur J Pharmacol; 1994 May 12; 257(1-2):53-8. PubMed ID: 8082707
    [Abstract] [Full Text] [Related]

  • 12. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P, Vieira-Coelho MA, Parada A.
    Pharmacol Toxicol; 2003 Jun 12; 92(6):272-8. PubMed ID: 12787259
    [Abstract] [Full Text] [Related]

  • 13. Conditioned place preference induced by a combination of L-dopa and a COMT inhibitor, entacapone, in rats.
    Katajamäki J, Honkanen A, Piepponen TP, Lindén IB, Zharkovsky A, Ahtee L.
    Pharmacol Biochem Behav; 1998 May 12; 60(1):23-6. PubMed ID: 9610919
    [Abstract] [Full Text] [Related]

  • 14. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P.
    J Neural Transm (Vienna); 2002 May 12; 109(1):53-67. PubMed ID: 11793162
    [Abstract] [Full Text] [Related]

  • 15. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S, Gordin A, Järvinen M, Wikberg T, Schultz E, Nissinen E, Pentikäinen PJ, Rita H.
    Clin Neuropharmacol; 1990 Oct 12; 13(5):436-47. PubMed ID: 2272023
    [Abstract] [Full Text] [Related]

  • 16. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
    Asanuma M, Miyazaki I.
    BMC Neurosci; 2016 Jul 25; 17(1):52. PubMed ID: 27456338
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M.
    Eur J Clin Pharmacol; 1999 Aug 25; 55(6):461-7. PubMed ID: 10492060
    [Abstract] [Full Text] [Related]

  • 18. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, Reinikainen K.
    Br J Clin Pharmacol; 2002 Oct 25; 54(4):363-71. PubMed ID: 12392583
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.
    Nissinen E, Lindén IB, Schultz E, Kaakkola S, Männistö PT, Pohto P.
    Eur J Pharmacol; 1988 Aug 24; 153(2-3):263-9. PubMed ID: 3181288
    [Abstract] [Full Text] [Related]

  • 20. Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.
    Gerlach M, van den Buuse M, Blaha C, Bremen D, Riederer P.
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Nov 24; 370(5):388-94. PubMed ID: 15502970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.